| Dr Jai H Gilliam, MD | |
|
100 Providence Way, Suite 200, Nicholasville, KY 40356-6031 | |
| (859) 260-5370 | |
| (859) 260-5379 |
| Full Name | Dr Jai H Gilliam |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 23 Years |
| Location | 100 Providence Way, Nicholasville, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558404343 | NPI | - | NPPES |
| 64111156 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 39604 (Kentucky) | Secondary |
| 207R00000X | Internal Medicine | 39604 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Health Lexington | Lexington, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kentucky Orthopedic Rehabilitation Llc | 0345157293 | 683 |
| Baptist Health Medical Group Inc | 5597867184 | 1912 |
News Archive
Kinetic Muscles, Inc., an innovator in robotic neurotherapy technology, today announced it has received a $2.8 million grant from the National Institute of Neurological Disorder and Stroke of the National Institutes of Health that will support delivery of KMI's revolutionary teletherapy service to stroke survivors in rural areas.
Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Moores Cancer Center at the University of California San Diego (UCSD) has filed an Investigational New Drug Application with the U.S. Food & Drug Administration ("FDA") for approval to test Nupen, Apricus Bio's proprietary, topical NexACT-based formulation of filgrastim (Neupogen).
A newly discovered antibiotic, produced by bacteria from a cystic fibrosis patient, could be used to treat cases of drug-resistant tuberculosis (TB). This is the finding of a team of scientists from Cardiff University's School of Biosciences and the University of Warwick.
InterMune, Inc. today announced that it has submitted an electronic New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Pirfenidone has been granted Orphan Drug and Fast Track designation by the FDA, and also has been granted Orphan Drug status in Europe.
› Verified 5 days ago
| Entity Name | Baptist Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518360296 PECOS PAC ID: 5597867184 Enrollment ID: O20150206000249 |
News Archive
Kinetic Muscles, Inc., an innovator in robotic neurotherapy technology, today announced it has received a $2.8 million grant from the National Institute of Neurological Disorder and Stroke of the National Institutes of Health that will support delivery of KMI's revolutionary teletherapy service to stroke survivors in rural areas.
Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Moores Cancer Center at the University of California San Diego (UCSD) has filed an Investigational New Drug Application with the U.S. Food & Drug Administration ("FDA") for approval to test Nupen, Apricus Bio's proprietary, topical NexACT-based formulation of filgrastim (Neupogen).
A newly discovered antibiotic, produced by bacteria from a cystic fibrosis patient, could be used to treat cases of drug-resistant tuberculosis (TB). This is the finding of a team of scientists from Cardiff University's School of Biosciences and the University of Warwick.
InterMune, Inc. today announced that it has submitted an electronic New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Pirfenidone has been granted Orphan Drug and Fast Track designation by the FDA, and also has been granted Orphan Drug status in Europe.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jai H Gilliam, MD Po Box 910670, Lexington, KY 40591-0670 Ph: (859) 971-4685 | Dr Jai H Gilliam, MD 100 Providence Way, Suite 200, Nicholasville, KY 40356-6031 Ph: (859) 260-5370 |
News Archive
Kinetic Muscles, Inc., an innovator in robotic neurotherapy technology, today announced it has received a $2.8 million grant from the National Institute of Neurological Disorder and Stroke of the National Institutes of Health that will support delivery of KMI's revolutionary teletherapy service to stroke survivors in rural areas.
Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Moores Cancer Center at the University of California San Diego (UCSD) has filed an Investigational New Drug Application with the U.S. Food & Drug Administration ("FDA") for approval to test Nupen, Apricus Bio's proprietary, topical NexACT-based formulation of filgrastim (Neupogen).
A newly discovered antibiotic, produced by bacteria from a cystic fibrosis patient, could be used to treat cases of drug-resistant tuberculosis (TB). This is the finding of a team of scientists from Cardiff University's School of Biosciences and the University of Warwick.
InterMune, Inc. today announced that it has submitted an electronic New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Pirfenidone has been granted Orphan Drug and Fast Track designation by the FDA, and also has been granted Orphan Drug status in Europe.
› Verified 5 days ago
Sharat Koul, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1250 Keene Rd Ste 102, Nicholasville, KY 40356 Phone: 859-276-4429 Fax: 859-276-4429 | |
Phillip H. Hoffman, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 100 Providence Way, Suite 200, Nicholasville, KY 40356 Phone: 859-260-5370 Fax: 859-260-5379 | |
Dr. Wendell Rance Miers, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 417 E Cambridge Ln, Nicholasville, KY 40356 Phone: 859-351-3801 | |
Benjamin Simms Cloyd, Internal Medicine Medicare: Medicare Enrolled Practice Location: 100 Providence Way Ste 200, Nicholasville, KY 40356 Phone: 859-260-5370 Fax: 859-260-5379 | |
Michael L. Mckinney, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Providence Way, Nicholasville, KY 40356 Phone: 859-260-5370 Fax: 859-260-5379 | |
Shawn Flynn, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1250 Keene Rd Ste 102, Nicholasville, KY 40356 Phone: 859-276-4429 Fax: 859-276-5919 | |
Dr. Andrew Ray Usery, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 110 Village Pkwy, Nicholasville, KY 40356 Phone: 859-887-8400 Fax: 859-885-8448 |